The AMSP drug safety program:: Methods and global results

被引:107
|
作者
Grohmann, R
Engel, RR
Rüther, E
Hippius, H
机构
[1] Univ Munich, Psychiat Klin, Dept Psychiat, D-80336 Munich, Germany
[2] Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany
关键词
D O I
10.1055/s-2004-815505
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The AMSP (Arzneimittelsicherheit in der Psychiatry) study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions Of routine clinical treatment. It developed out of the preceding drug surveillance study AMUP (Arzneimitteluberwachung in der Psychiatrie). Currently 35 hospitals participate in the Study. This paper describes the methods of the AMSP, gives detailed definitions of ADRs assessed to be "severe," and discusses the implications of these definitions and the methodological approach for evaluating the AMSP data. In addition, some overall data compiled on ADR rates from 1993 to 2000 are given.
引用
收藏
页码:S4 / S11
页数:8
相关论文
共 50 条
  • [1] Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program:: Methods and first results for tricyclic antidepressants and SSRI
    Grohmann, R
    Rüther, E
    Engel, RR
    Hippius, H
    PHARMACOPSYCHIATRY, 1999, 32 (01) : 21 - 28
  • [2] Assessment of sexual dysfunctions in schizophrenic inpatients with the AMSP drug safety program
    Linka, T
    Dittmann-Balcar, A
    Grohmann, R
    Bender, S
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 361 - 362
  • [3] Severe adverse drug reactions of typical and atypical neuroleptics in routine clinical treatment:: results from the AMSP drug safety program
    Bender, S
    Linka, T
    Grohmann, R
    Engel, RR
    Degner, D
    Rüther, E
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 214 - 214
  • [4] Inventing a Drug Safety Program for Psychiatric Inpatients: AMSP (Arzneimittelsicherheit in der Psychiatrie)
    A. Konstantinidis
    R. Grohmann
    E. Jaquenoud Sirot
    P. Stephan
    R. Engel
    S. Kasper
    Drug Safety, 2008, 31 : 885 - 885
  • [5] Inventing a Drug Safety Program for Psychiatric Inpatients: AMSP (Arzneimittelsicherheit in der Psychiatrie)
    Konstontinidis, A.
    Grohmann, R.
    Jaquenoud, Sirot E.
    Stephan, P.
    Engel, R.
    Kasper, S.
    DRUG SAFETY, 2008, 31 (10) : 952 - 952
  • [6] Severe adverse drug reactions of antidepressants:: Results of the German Multicenter Drug Surveillance Program AMSP
    Schmidt, LG
    Degner, D
    Grohmann, R
    Kropp, S
    Bender, S
    Engel, RR
    Rüther, E
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 261 - 261
  • [7] Severe adverse drug reactions of antidepressants:: Results of the German multicenter drug surveillance program AMSP
    Degner, D
    Grohmann, R
    Kropp, S
    Rüther, E
    Bender, S
    Engel, RR
    Schmidt, LG
    PHARMACOPSYCHIATRY, 2004, 37 : S39 - S45
  • [8] AMSP - A model for improved drug safety in epileptology?
    Schmidt, LG
    Grohmann, R
    AKTUELLE NEUROLOGIE, 2002, 29 : S54 - S57
  • [9] Drug safety in pyschiatry in pharmacotherapy -: The AMSP system
    Rüther, E
    Grohmann, R
    PSYCHOPHARMAKOTHERAPIE, 2004, 11 (03): : 95 - 95
  • [10] Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program
    Friedrich, Michaela-Elena
    Akimova, Elena
    Huf, Wolfgang
    Konstantinidis, Anastasios
    Papageorgiou, Konstantinos
    Winkler, Dietmar
    Toto, Sermin
    Greil, Waldemar
    Grohmann, Renate
    Kasper, Siegfried
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 (04):